Epigenetic reprogramming of monocytes in patients with coronary atherosclerosis

Completed

• Conditions: atherosclerosis; 10011082; 10003216

• Registration Number: NL-OMON38690
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

Patients (male/female), aged >18 years, admitted to the acute coronary unit of the CWZ hospital for evaluation of chest pain.
- No coronary atherosclerosis (TPS<=0): then participation in the control group.
- Severe atherosclerosis (TPS<=>6): then participation in the patient.

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Acute coronary syndrome (ST-segment elevation or depression and elevated plasma troponin levels)
- Use of statins or thrombocyte aggregation inhibitors (since these drugs have been shown to modulate epigenetic changes in in vitro studies). Of course, these drugs can be given after blood sampling if clinically indicated.
- Signs or symptoms of a current infection (fever, chills)
- Auto-immune diseases (such as rheumatoid arthritis)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Blood will be drawn immediately upon inclusion for isolation of monocytes. The<br /><br>primary endpoint is H3K4 trimethylation in the promoter region of inflammatory<br /><br>cytokines. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints is the cytokine release in response to stimulation with TLR<br /><br>agonists and foam cell formation</p><br>